NCT05734196 - The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

April 1, 2026

Conditions

Ectonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of InfancyATP-Binding Cassette Subfamily C Member 6 DeficiencyPseudoxanthoma Elasticum

Interventions

DRUG

INZ-701

Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Trial Locations (7)

19104

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

43205

RECRUITING

Nationwide Children's Hospital, Columbus

84108

RECRUITING

The University of Utah, Salt Lake City

92123

RECRUITING

Rady Children's Hospital, San Diego

02115

RECRUITING

Boston Children's Hospital, Boston

Unknown

NOT_YET_RECRUITING

Hospital Sant Joan de Déu, Barcelona

M13 9WL

RECRUITING

Royal Manchester Children's Hospital, Manchester